

Note: Please note that, with effect from 30th October 2015, a principal amount of USD1,133,453,000 of the USD Tier 2 subordinated notes (the "Notes") are no longer included in the capital base of Industrial and Commercial Bank of China (Asia) Limited (the "Issuer"). On 2 October 2015, the Issuer has allotted and issued 512,252,000 ordinary shares (the "New Shares") at a consideration of US\$1,650,000,000. The New Shares constitute Common Equity Tier 1 of the Issuer. For further details with respect to such issue, please refer to "Main Features Template – Ordinary Shares", which can be assessed by clicking "About Us \rightarrow Financial Information \rightarrow Main Features of Issued Capital Instruments" under of the homepage of the Issuer's website (www.icbcasia.com). Upon the inclusion of the New Shares as Common Equity Tier 1 of the Issuer, the Issuer's total Tier 1 capital has significantly improved and the Issuer has elected to no longer recognise the Notes in the principal amount of USD1,133,453,000 as Tier 2 capital of the Issuer. The Issuer will continue to recognise the remaining principal amount of USD500,000,000 of the Notes as Tier 2 capital for the purpose of further business development.

The revised details of the Notes are set out below.

1	Issuer	Industrial and Commercial Bank of China (Asia) Limited
2	Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement)	ICBCAS451224
3	Governing law(s) of the instrument	The Notes and any non- contractual obligations arising out of or in connection with the Notes will be governed by, and shall be construed in accordance with, English law, except that the provisions of the Notes relating to subordination shall be governed by, and construed in accordance with, the laws of Hong Kong.
	Regulatory treatment	
4	Transitional Basel III rules [#]	Tier 2
5	Post-transitional Basel III rules ⁺	Tier 2
6	Eligible at solo*/group/group & solo	Solo and Group
7	Instrument type (types to be specified by each jurisdiction)	Other Tier 2 instruments
8	Amount recognised in regulatory capital (Currency in million, as of most recent reporting date)	HK\$3,875 million (as of the date of de-recognition)
9	Par value of instrument	USD500 million
	Accounting classification	Liability – amortised cost
	Original date of issuance	30 December 2014
12	Perpetual or dated	Dated
13	Original maturity date	30 December 2024
14	Issuer call subject to prior supervisory approval	Yes
15	Optional call date, contingent call dates and redemption amount	30 December 2019 (Redemptions in whole at 100% with accrued interests)
16	Subsequent call dates, if applicable	N/A
	Coupons/dividends	
17	Fixed or floating dividend/coupon	Fixed
18	Coupon rate and any related index	4.5% per annum
19	Existence of a dividend stopper	N/A
20	Fully discretionary, partially discretionary or mandatory	Mandatory
21	Existence of step up or other incentive to redeem	N/A
22	Noncumulative or cumulative	Cumulative
23	Convertible or non-convertible	Non-convertible
24	If convertible, conversion trigger (s)	N/A
25	If convertible, fully or partially	N/A
26	If convertible, conversion rate	N/A
27	If convertible, mandatory or optional conversion	N/A
28	If convertible, specify instrument type convertible into	N/A
29	If convertible, specify issuer of instrument it converts into	N/A
30	Write-down feature	Yes

Main Features Template – USD subordinated note with a final maturity on 30 December 2024 (callable on 30 December 2019)



31	If write-down, write-down trigger(s)	Upon the occurrence of a Non- Viability Event
32	If write-down, full or partial	Full
33	If write-down, permanent or temporary	Permanent
34	If temporary write-down, description of write-up	N/A
35	Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	Depositors, bank's creditors, holders' of certificates of deposit issued and debt securities in issue.
36	Non-compliant transitioned features	No
37	If yes, specify non-compliant features	N/A

Footnote:

* Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rules

* Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rules

* Include solo-consolidated